CP
GRCE

Corbenic Partners’s Grace Therapeutics GRCE Stock Holding History

Corbenic Partners’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3
Closed – – 198
2017
Q1 		$0 Hold
3
– – ﹤0.01% 222
2016
Q4 		$0 Hold
3
– – ﹤0.01% 218
2016
Q3 		$0 Hold
3
– – ﹤0.01% 225
2016
Q2 		$0 Hold
3
– – ﹤0.01% 191
2016
Q1 		$0 Hold
3
– – ﹤0.01% 194
2015
Q4 		$0 Hold
3
– – ﹤0.01% 204
2015
Q3 		$0 Hold
3
– – ﹤0.01% 181
2015
Q2 		$0 Hold
3
– – ﹤0.01% 161
2015
Q1 		$1K Hold
3
– – ﹤0.01% 153
2014
Q4 		$1K Hold
3
– – ﹤0.01% 217
2014
Q3 		$1K Hold
3
– – ﹤0.01% 133
2014
Q2 		$1K Hold
3
– – ﹤0.01% 106
2014
Q1 		$1K Buy
+3
New +$1.83K ﹤0.01% 106

Other funds holding GRCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Corbenic Partners's GRCE Position: Q2 2017 in Review

Corbenic Partners sold out of Grace Therapeutics (GRCE) in Q2 2017, closing a stake of 3 shares.

Corbenic Partners first reported a position in GRCE in Q1 2014 and held it in 13 quarters. The position peaked at $1K in Q1 2015. 9 funds tracked by Wall St. Rank hold GRCE as of Q2 2017.

  • Corbenic Partners reported no remaining Grace Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Corbenic Partners sold 3 Grace Therapeutics shares in Q2 2017.
  • Corbenic Partners first reported a position in Grace Therapeutics in Q1 2014 and held it in 13 quarters.
  • Corbenic Partners's Grace Therapeutics position peaked at $1K in Q1 2015.
  • 9 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2017.

Based on Corbenic Partners's 13F filing for Q2 2017, filed 14 Aug 2017.